CEO Dr. Raza Bokhari talked with Proactive about the company’s newly reported topline Phase 2 results for its microneedle ...

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics ...

Medicus Pharma (NASDAQ:MDCX) said on Thursday that its experimental microneedle-based therapy showed encouraging efficacy in ...

As shelf-stable microarray patch (MAP) platforms move through development and clinical work, a ‘packaging first’ mentality is ...

Medicus Pharma Ltd. has announced that its Investigational New Animal Drug for a dissolvable Doxorubicin-containing microneedle array (D-MNA) has received Minor Use in Major Species Designation (MUMS) ...

An engineer from Purdue University has developed a new method of treating wounds for people who suffer from diabetic foot ulcers. Rahim Rahimi is an assistant professor in the School of Materials ...

Primary tissues are fixed by the magnetic microneedle scaffold and cut into small pieces by a slicing device, which are imparted with magnetic responsiveness because of the encapsulated microneedle ...

Researchers have used 3D-printing technology to improve the viral titer of microneedle array patches, resulting in effective immunogenicity and protection against infection in mice. (Nanowerk News) ...

Fabrication process and actual image of the silicon-based neural microelectrode array. a 1800 μm thick double-polished silicon wafer. b Microneedle array root fabrication with etching. c Microneedle ...